Landscapes / Companies

Beijing InnoCare Pharma Tech Co., Ltd. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
3 in Phase 3
Next date
ICP-332, Phase 3 trial completes
Drugs
17
in active trials · 22 in all
Trials
29 active
60 since 2021

Drugs17

DrugHow it worksPartnerStageNext dateDetails
Bruton's tyrosine kinase inhibitor
Approved in China 31 Aug 2028Phase 3 trial completes
Monoclonal antibody
Approved in China Sep 2028Phase 3 trial completes
—
Phase 3 25 Nov 2026soonPhase 3 trial completes
—
Phase 3 Mar 2027Phase 2 trial completes
Mesutoclaxnot checked
—
Phase 3 Dec 2027Phase 2 trial completes
—
Phase 1/2 28 Dec 2026Phase 1/2 trial completes
—
Phase 2 Mar 2027Phase 2 trial completes
—
Phase 1/2 Sep 2027Phase 1/2 trial completes
—
Phase 1/2 25 Dec 2027Phase 1/2 trial completes
—
Phase 1/2 Jul 2028Phase 1/2 trial completes
—
Phase 1/2 Dec 2030Phase 1/2 trial completes
—
Phase 2 —
—
Phase 1 Mar 2028Phase 1 trial completes
—
Phase 1 Jun 2029Phase 1 trial completes
—
Phase 1 —
—
Phase 1 —
—
Phase 1 —

About

No active trial
ICP-033, ICP-105, ICP-189, Orelabrutinib and R-CHOP, Recombinant humanized monoclonal antibody MIL62
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Beijing InnoCare Pharma Tech Co., Ltd.

Following is part of Solo: you see every change to Beijing InnoCare Pharma Tech Co., Ltd. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in